73 results on '"Tolios A"'
Search Results
2. Digital competence in laboratory medicine
- Author
-
Adler Jakob, Lenski Marie, Tolios Alexander, Taie Santiago Fares, Sopic Miron, Rajdl Daniel, Rampul Ashlin, Sancesario Giulia, and Biemann Ronald
- Subjects
artificial intelligence ,data science ,digital competence ,digitalization ,skills ,Medical technology ,R855-855.5 - Abstract
Even though most physicians and professionals in laboratory medicine have received basic training in statistics, experience shows that a general understanding of data analysis is not yet available on a broad scale. Therefore, data literacy, data-driven decision making, and computational thinking should be implemented in future educational training. To evaluate the state of digital competence among young scientists (YS) in laboratory medicine, we launched a worldwide online survey.
- Published
- 2023
- Full Text
- View/download PDF
3. Requirements for electronic laboratory reports according to the German guideline Rili-BAEK and ISO 15189
- Author
-
Bietenbeck Andreas, Cadamuro Janne, Holdenrieder Stefan, Leichtle Alexander Benedikt, Ludwig Amei, von Meyer Alexander, Nauck Matthias, Orth Matthias, Özçürümez Mustafa, Ponader Alexander, Streichert Thomas, Strobl Dominik, Tolios Alexander, Wiegel Bernhard, and Gassner Ulrich
- Subjects
electronic laboratory report ,electronic patient record ,iso 15189 ,regulation ,rili-baek ,Medical technology ,R855-855.5 - Abstract
Legal regulations and guidelines such as the Guidelines of the German Medical Association for the Quality Assurance of Laboratory Medical Examinations (Rili-BAEK) and ISO 15189 apply to electronic laboratory reports. However, many laboratories struggle with practical implementation of these regulations and guidelines.
- Published
- 2021
- Full Text
- View/download PDF
4. Gender mobility in the labor market with skills-based matching models
- Author
-
Adhikari, Ajaya, Vethman, Steven, Vos, Daan, Lenz, Marc, Cocu, Ioana, Tolios, Ioannis, and Veenman, Cor J.
- Published
- 2024
- Full Text
- View/download PDF
5. The common VTE-protective G haplotype of F5 increases factor V-short, TFPI function, and risk of bleeding
- Author
-
Sims, Matthew C., Gierula, Magdalena, Stephens, Jonathan C., Tokolyi, Alex, Stefanucci, Luca, Persyn, Elodie, Sun, Luanluan, Collins, Janine H., Davenport, Emma E., Di Angelantonio, Emanuele, Downes, Kate, Inouye, Michael, Paul, Dirk S., Thomas, Will, Tolios, Alexander, Ouwehand, Willem H., Gleadall, Nicholas S., Crawley, James T. B., Butterworth, Adam S., Frontini, Mattia, and Ahnström, Josefin
- Published
- 2024
- Full Text
- View/download PDF
6. A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo
- Author
-
Caban, Monika, Koblmueller, Bettina, Groza, Diana, Schueffl, Hemma H., Terenzi, Alessio, Tolios, Alexander, Mohr, Thomas, Mathuber, Marlene, Kryeziu, Kushtrim, Jaunecker, Carola, Pirker, Christine, Keppler, Bernhard K., Berger, Walter, Kowol, Christian R., and Heffeter, Petra
- Published
- 2023
- Full Text
- View/download PDF
7. The necessity of repeat testing for von Willebrand disease in adult patients with mild to moderate bleeding disorders
- Author
-
Mehic, Dino, Kraemmer, Daniel, Tolios, Alexander, Bücheler, Julia, Quehenberger, Peter, Haslacher, Helmuth, Ay, Cihan, Pabinger, Ingrid, and Gebhart, Johanna
- Published
- 2023
- Full Text
- View/download PDF
8. SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020
- Author
-
Quante, Markus, Brake, Linda, Tolios, Alexander, Della Penna, Andrea, Steidle, Christoph, Gruendl, Magdalena, Grishina, Anna, Haeberle, Helene, Guthoff, Martina, Tullius, Stefan G., Königsrainer, Alfred, Nadalin, Silvio, and Löffler, Markus W.
- Published
- 2021
- Full Text
- View/download PDF
9. Joining European Scientific Forces to Face Pandemics
- Author
-
Vasconcelos, M. Helena, Alcaro, Stefano, Arechavala-Gomeza, Virginia, Baumbach, Jan, Borges, Fernanda, Brevini, Tiziana A.L., Rivas, Javier De Las, Devaux, Yvan, Hozak, Pavel, Keinänen-Toivola, Minna M., Lattanzi, Giovanna, Mohr, Thomas, Murovska, Modra, Prusty, Bhupesh K., Quinlan, Roy A., Pérez-Sala, Dolores, Scheibenbogen, Carmen, Schmidt, Harald H.H.W., Silveira, Isabel, Tieri, Paolo, Tolios, Alexander, and Riganti, Chiara
- Published
- 2021
- Full Text
- View/download PDF
10. Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency
- Author
-
Mehic, Dino, Tolios, Alexander, Hofer, Stefanie, Ay, Cihan, Haslacher, Helmuth, Rejtö, Judit, Ouwehand, Willem H., Downes, Kate, Haimel, Matthias, Pabinger, Ingrid, and Gebhart, Johanna
- Published
- 2021
- Full Text
- View/download PDF
11. Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions
- Author
-
Tolios, A., De Las Rivas, J., Hovig, E., Trouillas, P., Scorilas, A., and Mohr, T.
- Published
- 2020
- Full Text
- View/download PDF
12. Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders
- Author
-
Downes, Kate, Megy, Karyn, Duarte, Daniel, Vries, Minka, Gebhart, Johanna, Hofer, Stefanie, Shamardina, Olga, Deevi, Sri V.V., Stephens, Jonathan, Mapeta, Rutendo, Tuna, Salih, Al Hasso, Namir, Besser, Martin W., Cooper, Nichola, Daugherty, Louise, Gleadall, Nick, Greene, Daniel, Haimel, Matthias, Martin, Howard, Papadia, Sofia, Revel-Vilk, Shoshana, Sivapalaratnam, Suthesh, Symington, Emily, Thomas, Will, Thys, Chantal, Tolios, Alexander, Penkett, Christopher J., Ouwehand, Willem H., Abbs, Stephen, Laffan, Michael A., Turro, Ernest, Simeoni, Ilenia, Mumford, Andrew D., Henskens, Yvonne M.C., Pabinger, Ingrid, Gomez, Keith, and Freson, Kathleen
- Published
- 2019
- Full Text
- View/download PDF
13. Time from venipuncture to cell isolation: Impact on granulocyte-reactive antibody testing
- Author
-
Schönbacher, Marlies, Mayr, Wolfgang R., Schulze, Torsten J., Leitner, Gerda, Schmidt, Claas, Hofbauer, Günther, Tolios, Alexander, and Körmöczi, Günther F.
- Published
- 2019
- Full Text
- View/download PDF
14. High Rate of Passenger Lymphocyte Syndrome after ABO Minor Incompatible Lung Transplantation.
- Author
-
Kohl, Mirjam M., Schwarz, Stefan, Jaksch, Peter, Muraközy, Gabriella, Kurz, Martin, Schönbacher, Marlies, Tolios, Alexander, Frommlet, Florian, Hoetzenecker, Konrad, and Körmöczi, Günther F.
- Subjects
BLOOD group incompatibility ,LUNG transplantation ,BLOOD groups ,ERYTHROCYTES ,BLOOD transfusion ,BLOOD platelet transfusion ,KIDNEY transplantation - Abstract
Rationale: Passenger lymphocyte syndrome (PLS) may complicate minor ABO mismatched lung transplantation (LuTX) via donor-derived red cell antibody-induced hemolysis. Objectives: To ascertain the incidence and specificity of PLS-relevant antibodies among the study population as well as the dynamics of hemolysis parameters and the transfusion requirement of patients with or without PLS. Methods: In this cohort study, 1,011 patients who received LuTX between January 2010 and June 2019 were studied retrospectively. Prospectively, 87 LuTX (July 2019 to June 2021) were analyzed. Postoperative ABO antibody and hemolytic marker determinations, transfusion requirement, and duration of postoperative hospital care were analyzed. Retrospectively, blood group A recipients of O grafts with PLS were compared with those without. Measurements and Main Results: PLS affected 18.18% (retrospective) and 30.77% (prospective) of A recipients receiving O grafts, 5.13% of B recipients of O grafts, and 20% of AB patients receiving O transplants. Anti-A and anti-A
1 were the predominant PLS-inducing antibodies, followed by anti-B and anti-A,B. Significantly lower hemoglobin values (median, 7.4 vs. 8.3 g/dl; P = 0.0063) and an approximately twice as high percentage of patients requiring blood transfusions were seen in PLS. No significant differences in other laboratory markers, duration of hospital stay, or other complications after LuTX were registered. Conclusions: Minor ABO incompatible LuTX recipients are at considerable risk of developing clinically significant PLS. Post-transplant monitoring combining red cell serology and hemolysis marker determination appears advisable so as not to overlook hemolytic episodes that necessitate antigen-negative transfusion therapy. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
15. Cardio-anesthesiology considerations for the trans-catheter aortic valve implantation (TAVI) procedure
- Author
-
Melidi, Eleni, Latsios, George, Toutouzas, Kostas, Vavouranakis, Manolis, Tolios, Ioannis, Gouliami, Maria, Gerckens, Ulrich, and Tousoulis, Dimitris
- Published
- 2016
- Full Text
- View/download PDF
16. Cardio-anesthesiology considerations for the trans-catheter aortic valve implantation (TAVI) procedure
- Author
-
Eleni Melidi, George Latsios, Kostas Toutouzas, Manolis Vavouranakis, Ioannis Tolios, Maria Gouliami, Ulrich Gerckens, and Dimitris Tousoulis
- Subjects
Anesthesia ,Trans-catheter aortic valve implantation ,Aortic valve stenosis ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Transcatheter aortic valve implantation (TAVI) has become the mainstay for high-risk or inoperable patients with symptomatic aortic valve stenosis, and research regarding the use of transcatheter valves in intermediate or low-risk patients is currently ongoing. The aim of this article is to provide comprehensive insight into the anesthetic management of patients undergoing TAVI and to highlight possible gaps in the current knowledge. One important procedural characteristic that is imperative to consider is the type of anesthesia being used and its possible complications. Increasingly, experienced centers have changed from general anesthesia with endotracheal intubation to local anesthesia with sedation, especially when the transfemoral access route is used for TAVI. There is still debate regarding what type of anesthesia should be used in the procedure, and the lack of randomized data makes it even more challenging for the operators.
- Published
- 2016
- Full Text
- View/download PDF
17. Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols
- Author
-
Löffler, Markus W., Schuster, Heiko, Zeck, Anne, Quilitz, Nicolas, Weinreich, Jürgen, Tolios, Alexander, Haen, Sebastian P., Horvath, Philipp, Löb, Stefan, Rammensee, Hans-Georg, Königsrainer, Ingmar, Königsrainer, Alfred, and Beckert, Stefan
- Published
- 2017
- Full Text
- View/download PDF
18. Potentials and pitfalls of ChatGPT and natural-language artificial intelligence models for the understanding of laboratory medicine test results. An assessment by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group on Artificial Intelligence (WG-AI)
- Author
-
Cadamuro, Janne, Cabitza, Federico, Debeljak, Zeljko, De Bruyne, Sander, Frans, Glynis, Perez, Salomon Martin, Ozdemir, Habib, Tolios, Alexander, Carobene, Anna, and Padoan, Andrea
- Subjects
SWARM intelligence ,CHATGPT ,ARTIFICIAL intelligence ,NATURAL language processing ,CHEMICAL laboratories ,EUROPEAN integration - Abstract
ChatGPT, a tool based on natural language processing (NLP), is on everyone's mind, and several potential applications in healthcare have been already proposed. However, since the ability of this tool to interpret laboratory test results has not yet been tested, the EFLM Working group on Artificial Intelligence (WG-AI) has set itself the task of closing this gap with a systematic approach. WG-AI members generated 10 simulated laboratory reports of common parameters, which were then passed to ChatGPT for interpretation, according to reference intervals (RI) and units, using an optimized prompt. The results were subsequently evaluated independently by all WG-AI members with respect to relevance, correctness, helpfulness and safety. ChatGPT recognized all laboratory tests, it could detect if they deviated from the RI and gave a test-by-test as well as an overall interpretation. The interpretations were rather superficial, not always correct, and, only in some cases, judged coherently. The magnitude of the deviation from the RI seldom plays a role in the interpretation of laboratory tests, and artificial intelligence (AI) did not make any meaningful suggestion regarding follow-up diagnostics or further procedures in general. ChatGPT in its current form, being not specifically trained on medical data or laboratory data in particular, may only be considered a tool capable of interpreting a laboratory report on a test-by-test basis at best, but not on the interpretation of an overall diagnostic picture. Future generations of similar AIs with medical ground truth training data might surely revolutionize current processes in healthcare, despite this implementation is not ready yet. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Stimulation of Platelet Death by Vancomycin
- Author
-
Syeda T. Towhid, Eva-Maria Schmidt, Alexander Tolios, Patrick Münzer, Evi Schmid, Oliver Borst, Meinrad Gawaz, Evi Stegmann, and Florian Lang
- Subjects
Platelets ,Phosphatidylserine ,Caspase-3 ,Apoptosis ,Cell membrane scrambling ,Mitochondrial potential ,Ca2+ ,Physiology ,QP1-981 ,Biochemistry ,QD415-436 - Abstract
Background/Aims: Side effects of vancomycin, a widely used antibiotic, include thrombocytopenia. The vancomycin-induced thrombocytopenia has been attributed to immune reactions. At least in theory, thrombocytopenia could result in part from the triggering of apoptosis, which results in cell shrinkage and cell membrane scrambling with subsequent phosphatidylserine exposure at the cell surface. The cell membrane scrambling could be initiated by a signaling involving increase of cytosolic Ca2+ activity, ceramide formation, mitochondrial depolarization and/or caspase activation. Vancomycin has indeed been shown to trigger neutrophil apoptosis. An effect of vancomycin on platelet apoptosis has, however, never been tested. The present study thus explored the effect of vancomycin on platelet activation and apoptosis. Methods: Human blood platelets were exposed to vancomycin and forward scatter was utilized to estimate cell volume, annexin V-binding to quantify phosphatidylserine (PS) exposure, Fluo-3 AM fluorescence to estimate cytosolic Ca2+ activity ([Ca2+]i), antibodies to quantify ceramide formation and immunofluorescence to quantify protein abundance of active caspase-3. Results: A 30 minutes exposure to vancomycin (≥1 µg/ ml) decreased cell volume, triggered annexin V-binding, increased [Ca2+]i, activated caspase 3, stimulated ceramide formation, triggered release of thromboxane B2, and upregulated surface expression of CD62P (P-selectin) as well as activated integrin αllbβ3. Annexin V-binding and upregulation of CD62P (P-selectin) and integrin αllbβ3 was significantly blunted by removal of extracellular Ca2+. Annexin V-binding was not significantly blunted by pan-caspase inhibitor zVAD-FMK (1 µM). In conclusion, vancomycin results in platelet activation and suicidal platelet death with increase of [Ca2+]i, caspase-3 activation, cell membrane scrambling and cell shrinkage. Activation and cell membrane scrambling required the presence of Ca2+, but not activation of caspases. Conclusion: Vancomycin exposure leads to platelet activation and apoptosis.
- Published
- 2013
- Full Text
- View/download PDF
20. Immune Checkpoint and EMT-Related Molecules in Circulating Tumor Cells (CTCs) from Triple Negative Breast Cancer Patients and Their Clinical Impact.
- Author
-
Vardas, Vasileios, Tolios, Anastasios, Christopoulou, Athina, Georgoulias, Vassilis, Xagara, Anastasia, Koinis, Filippos, Kotsakis, Athanasios, and Kallergi, Galatea
- Subjects
- *
STATISTICS , *EXPERIMENTAL design , *PROGRAMMED death-ligand 1 , *IMMUNE checkpoint proteins , *FLUOROIMMUNOASSAY , *GENE expression , *TREATMENT effectiveness , *SEVERITY of illness index , *DESCRIPTIVE statistics , *RESEARCH funding , *DATA analysis , *BREAST tumors , *OVERALL survival , *PHENOTYPES - Abstract
Simple Summary: A better understanding of the molecular mechanisms that govern metastasis and the identification of early therapeutic approaches to prevent the dissemination of tumor cells in triple negative breast cancer (TNBC) patients is highly important. The present study focuses on investigating the expression of immune checkpoint molecules (PD-L1, CTLA-4) and epithelial to mesenchymal transition (EMT)-related proteins (detyrosinated α-tubulin (GLU) and vimentin (VIM)) in TNBC patients' CTCs and assess their relations to disease severity and clinical outcome. All the examined biomarkers were found to be expressed in CTCs, whereas PD-L1, GLU, and VIM were related to worse overall survival (OS) in TNBC patients. Our data demonstrate the importance of these four biomarkers for TNBC patients and provide an interesting tool for stratifying patients that could benefit from a potential combination of novel therapies. Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype. There are few targeted therapies for these patients, leading to an unmet need for new biomarkers. The present study aimed to investigate the expression of PD-L1, CTLA-4, GLU, and VIM in CTCs of TNBC patients. Ninety-five patients were enrolled in this study: sixty-four TNBC and thirty-one luminal. Of these patients, 60 were in the early stage, while 35 had metastatic disease. Protein expression was identified by immunofluorescence staining experiments and VyCAP analysis. All the examined proteins were upregulated in TNBC patients. The expression of the GLU+VIM+CK+ phenotype was higher (50%) in metastatic TNBC compared to early TNBC patients (17%) (p = 0.005). Among all the BC patients, a significant correlation was found between PD-L1+CD45−CK+ and CTLA-4+CD45−CK+ phenotypes (Spearman test, p = 0.024), implying an important role of dual inhibition in BC. Finally, the phenotypes GLU+VIM+CK+ and PD-L1+CD45−CK+ were associated with shorter OS in TNBC patients (OS: log-rank p = 0.048, HR = 2.9, OS: log-rank p < 0.001, HR = 8.7, respectively). Thus, PD-L1, CTLA-4, GLU, and VIM constitute significant biomarkers in TNBC associated with patients' outcome, providing new therapeutic targets for this difficult breast cancer subtype. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. The effects of conflicting schemas on recall
- Author
-
Athanasios, Tolios
- Published
- 2010
- Full Text
- View/download PDF
22. INTERCEPT Pathogen Reduction in Platelet Concentrates, in Contrast to Gamma Irradiation, Induces the Formation of trans -Arachidonic Acids and Affects Eicosanoid Release during Storage.
- Author
-
Leitner, Gerda C., Hagn, Gerhard, Niederstaetter, Laura, Bileck, Andrea, Plessl-Walder, Kerstin, Horvath, Michaela, Kolovratova, Vera, Tanzmann, Andreas, Tolios, Alexander, Rabitsch, Werner, Wohlfarth, Philipp, and Gerner, Christopher
- Subjects
BLOOD platelets ,BLOOD platelet aggregation ,UNSATURATED fatty acids ,BLOOD products ,ULTRAVIOLET radiation ,IRRADIATION - Abstract
Pathogen inactivation techniques for blood products have been implemented to optimize clinically safe blood components supply. The INTERCEPT system uses amotosalen together with ultraviolet light wavelength A (UVA) irradiation. Irradiation-induced inactivation of nucleic acids may actually be accompanied by modifications of chemically reactive polyunsaturated fatty acids known to be important mediators of platelet functions. Thus, here, we investigated eicosanoids and the related fatty acids released upon treatment and during storage of platelet concentrates for 7 days, complemented by the analysis of functional and metabolic consequences of these treatments. Metabolic and functional issues like glucose consumption, lactate formation, platelet aggregation, and clot firmness hardly differed between the two treatment groups. In contrast to gamma irradiation, here, we demonstrated that INTERCEPT treatment immediately caused new formation of trans-arachidonic acid isoforms, while 11-hydroxyeicosatetraenoic acid (11-HETE) and 15-HETE were increased and two hydroperoxyoctadecadienoic acid (HpODE) isoforms decreased. During further storage, these alterations remained stable, while the release of 12-lipoxygenase (12-LOX) products such as 12-HETE and 12-hydroxyeicosapentaenoic acid (12-HEPE) was further attenuated. In vitro synthesis of trans-arachidonic acid isoforms suggested that thiol radicals formed by UVA treatment may be responsible for the INTERCEPT-specific effects observed in platelet concentrates. It is reasonable to assume that UVA-induced molecules may have specific biological effects which need to be further investigated. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Platelet function analyzer (PFA-100) in patients with bleeding disorder of unknown cause.
- Author
-
Mehic, D., Eichinger, B., Dreier, T., Rast, J., Tolios, A., Eichelberger, B., Kaider, A., Ay, C., Pabinger, I., and Gebhart, J.
- Published
- 2024
- Full Text
- View/download PDF
24. Assay validity of point-of-care platelet function tests in thrombocytopenic blood samples.
- Author
-
Lacom, Conrad, Tolios, Alexander, Löffler, Markus W., Eichelberger, Beate, Quehenberger, Peter, Schaden, Eva, and Wiegele, Marion
- Subjects
- *
PLATELET function tests , *BLOOD sampling , *PLATELET count , *BLOOD testing , *FLOW cytometry , *BLOOD platelets - Abstract
Introduction: Point-of-care (POC) platelet function tests are faster and easier to perform than in-depth assessment by flow cytometry. At low platelet counts, however, POC tests are prone to assess platelet function incorrectly. Lower limits of platelet count required to obtain valid test results were defined and a testing method to facilitate comparability between different tests was established. Materials and methods: We assessed platelet function in whole blood samples of healthy volunteers at decreasing platelet counts (> 100, 80-100, 50-80, 30-50 and < 30 x109/L) using two POC tests: impedance aggregometry and in-vitro bleeding time. Flow cytometry served as the gold standard. The number of platelets needed to reach 50% of the maximum function (ED50) and the lower reference limit (EDref) were calculated to define limits of test validity. Results: The minimal platelet count required for reliable test results was 100 x109/L for impedance aggregometry and in-vitro bleeding time but only 30 x109/L for flow cytometry. Comparison of ED50 and EDref showed significantly lower values for flow cytometry than either POC test (P value < 0.05) but no difference between POC tests nor between the used platelet agonists within a test method. Conclusion: Calculating the ED50 and EDref provides an effective way to compare values from different platelet function assays. Flow cytometry enables correct platelet function testing as long as platelet count is > 30 x109/L whereas impedance aggregometry and in-vitro bleeding time are inconsistent unless platelet count is > 100 x109/L. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Thrombomodulin in patients with mild to moderate bleeding tendency.
- Author
-
Mehic, Dino, Tolios, Alexander, Hofer, Stefanie, Ay, Cihan, Haslacher, Helmuth, Downes, Kate, Haimel, Matthias, Pabinger, Ingrid, and Gebhart, Johanna
- Subjects
- *
HEMORRHAGE , *THROMBOMODULIN , *GENETIC variation , *PLASMA production - Abstract
Introduction: A massive increase of soluble thrombomodulin (sTM) due to variants in the thrombomodulin gene (THBD) has recently been identified as a novel bleeding disorder. Aim: To investigate sTM levels and underlying genetic variants as a cause for haemostatic impairment and bleeding in a large number of patients with a mild to moderate bleeding disorder (MBD), including patients with bleeding of unknown cause (BUC). Patients and methods: In 507 MBD patients, sTM levels, thrombin generation and plasma clot formation were measured and compared to 90 age‐ and sex‐matched healthy controls. In patients, genetic analysis of the THBD gene was performed. Results: No difference in sTM levels between patients and controls was found overall (median ([IQR] 5.0 [3.8‐6.3] vs. 5.1 [3.7‐6.4] ng/ml, p =.762), and according to specific diagnoses of MBD or BUC, and high sTM levels (≥95th percentile of healthy controls) were not overrepresented in patients. Soluble TM levels had no impact on bleeding severity or global tests of haemostasis, including thrombin generation or plasma clot formation. In the THBD gene, no known pathogenic or novel disease‐causing variants affecting sTM plasma levels were identified in our patient cohort. Conclusion: TM‐associated coagulopathy appears to be rare, as it was not identified in our large cohort of patients with MBD. Soluble TM did not arise as a risk factor for bleeding or altered haemostasis in these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Transvenous extraction of permanent pacemaker and defibrillator leads: Reduced procedural complexity and higher procedural success rates in patients with infective versus noninfective indications.
- Author
-
Archontakis, Stefanos, Pirounaki, Maria, Aznaouridis, Konstantinos, Karageorgopoulos, Drosos, Sideris, Konstantinos, Tolios, Panagiotis, Triantafyllou, Konstantinos, Gatzoulis, Konstantinos, Tousoulis, Dimitrios, and Sideris, Skevos
- Subjects
ENDOCARDITIS ,CARDIAC pacemakers ,CARDIAC tamponade ,ELECTRODES ,IMPLANTABLE cardioverter-defibrillators ,ARTIFICIAL implants ,INFECTION ,LONGITUDINAL method ,EVALUATION of medical care ,COMPLICATIONS of prosthesis ,SURGICAL complications ,MEDICAL device removal ,DESCRIPTIVE statistics - Abstract
Introduction: Transvenous lead extraction (TLE) is critical in the long‐term management of patients with cardiac implanted electronic devices (CIEDs). The aim of the study is to evaluate the outcomes of TLE and to investigate the impact of infection. Methods and Results: Data of patients undergoing extraction of permanent pacemaker and defibrillator leads during October 2014–September 2019 were prospectively analyzed. Overall, 242 consecutive patients (aged 71.0 ± 14.0 years, 31.4% female), underwent an equal number of TLE operations for the removal of 516 leads. Infection was the commonest indication (n = 201, 83.1%). Mean implant‐to‐extraction duration was 7.6 ± 5.4 years. Complete procedural success was recorded in 96.1%, and clinical procedural success was achieved in 97.1% of attempted lead extractions. Major complications occurred in two (0.8%) and minor complications in seven (2.9%) patients. Leads were removed exclusively by using locking stylets in 65.7% of the cases. In the subgroup of noninfective patients, advanced extraction tools were more frequently required compared to patients with CIED infections, to extract leads (success only with locking stylet: 55.8% vs. 67.8%, p =.032). In addition, patients without infection demonstrated lower complete procedural success rates (90.7% vs. 97.2%, p =.004), higher major complication rates (2.4% vs. 0.5%, p =.31) and longer procedural times (136 ± 13 vs. 111 ± 15 min, p =.001). Conclusions: Our data demonstrate high procedural efficacy and safety and indicate that in patients with noninfective indications, the procedure is more demanding, thus supporting the hypothesis that leads infection dissolves and/or prohibits the formation of fibrotic adherences. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. The assessment of platelet function by thromboelastometry as a point-of-care test to guide Intercept-treated platelet support in hemato-oncological patients and hematopoietic stem cell transplantation recipients.
- Author
-
Leitner, Gerda C., Ho, Markus, Tolios, Alexander, Hopfinger, Georg, Rabitsch, Werner, and Wohlfarth, Philipp
- Subjects
HEMATOPOIETIC stem cell transplantation ,BONE marrow transplantation ,PLATELET function tests ,BLOOD platelets ,POINT-of-care testing ,TUMOR treatment ,RESEARCH ,HOMOGRAFTS ,CLINICAL trials ,RESEARCH methodology ,THROMBELASTOGRAPHY ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,BLOOD platelet transfusion ,TUMORS ,LONGITUDINAL method - Abstract
Background: Pathogen inactivation (PI) techniques for platelet concentrates (PCs) are one of the latest innovations to improve blood safety and reduce the risk of transfusion-transmitted infections (TTIs). An impaired function and in vivo recovery of platelets as well as an increased PC demand are concerns regarding these techniques. The intent of this study was to evaluate the hemostatic effect of PCs treated with the Intercept™ System by thromboelastometry (TEM) and to assess the clinical validity of its results in comparison to post-transfusion increase (PTI) and corrected count increment (CCI).Study-design and Methods: This prospective-observational study included 47 patients (m:f = 25:22; median age: 54 years [21-70]) of our Bone Marrow Transplantation unit with hemato-oncological malignancies transfused with Intercept™-treated PCs. Serial TEM measurements were performed just before and 1 hour after PC transfusion and were analyzed for their correlation with PTI and CCI as well as for clinical variables.Results: The majority of our patients had received a hematopoietic stem cell transplantation (HSCT) (n = 41; 87%). In median 9 (1-50) PCs were transfused. Serial TEM, PTI, and CCI measurements were available for 150 transfusion episodes. The median platelet dose transfused was 2.65 × 1011 /unit (1.8-6). The median CCI was 9.250 (0-28.000). We observed a significant improvement in TEM parameters (p < 0.05) after transfusion of PI PCs, which did not mandatory correlate with the 1-hour PTI and CCI.Conclusion: Serial TEM measurements indicate the hemostatic effect of Intercept™-treated PCs. The 1-hour PTI and CCI may not appropriately reflect the in vivo function of platelets after PI PC transfusion. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
28. Percutaneous lead extraction and repositioning: An effective and safe therapeutic strategy for early ventricular lead perforation with dislocation both inside and outside the pericardial sac following a cardiac device implantation.
- Author
-
Archontakis, Stefanos, Sideris, Konstantinos, Aggeli, Konstantina, Gatzoulis, Konstantinos, Demosthenous, Michael, Tolios, Panagiotis, Lozos, Vasilios, Koumallos, Nikolas, Limperiadis, Dimitrios, Tousoulis, Dimitrios, Kallikazaros, Ioannis, and Sideris, Skevos
- Subjects
CATHETER ablation ,CARDIAC pacemakers ,IMPLANTABLE cardioverter-defibrillators ,ELECTROPHYSIOLOGY ,ORTHOPEDIC traction ,COMPLICATIONS of prosthesis ,REOPERATION ,THORACOTOMY ,THERAPEUTICS - Abstract
Introduction: Cardiac perforation of the right ventricle associated with pacemaker or implantable cardioverter defibrillator (ICD) leads' implantation is uncommon, albeit potentially life‐threatening, complication. The aim of this study is to further identify the optimal therapeutic strategy, especially when lead dislocation has occurred outside the pericardial sac. Methods and Results: The study population included 10 consecutive patients (six female, mean age: 66.5 years old) diagnosed with early ventricular lead perforation following a pacemaker or ICD implantation, with significant protrusion inside the pericardial sac (n = 2) or migration of the lead at the pleural space (n = 3), the diaphragm (n = 1), or the abdominal cavity (n = 4), during the period 2013‐2017. All patients were symptomatic; however, individuals presenting with hemodynamic instability were excluded. The outcome of the percutaneous therapeutic approach was retrospectively assessed. All patients underwent a successful removal of the perforating lead percutaneously at the electrophysiology lab, by direct traction, and repositioning in another location of the right ventricle. The operation was performed by a multidisciplinary team, under continuous hemodynamic and transesophageal echocardiographic monitoring and cardiac surgical backup. The periprocedural period was uneventful. Subjects were followed up for at least 1 year. Interestingly, all patients developed a type of postcardiac injury syndrome, successfully treated with a 3‐month regimen of ibuprofen and colchicine. Conclusion: Percutaneous traction and repositioning of the perforating ventricular lead are effective, safe, and less invasive compared with the thoracotomy method in hemodynamically stable patients when dislocation has occurred outside the pericardial sac provided that there is no visceral organs injury. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
29. The Innovative Canadian Pharmacogenomic Screening Initiative in Community Pharmacy (ICANPIC) study.
- Author
-
Papastergiou, John, Tolios, Peter, Li, Wilson, and Li, Jane
- Subjects
MEDICATION safety ,DRUG efficacy ,GENETIC disorders ,GENETIC disorder treatment ,MEDICAL screening ,DRUG therapy ,DRUG metabolism ,PHARMACOGENOMICS ,PATIENTS ,DRUGSTORES ,PHARMACISTS ,OCCUPATIONAL roles ,EVALUATION of human services programs - Abstract
Objectives: The safety and efficacy of medications can vary significantly between patients as a result of genetic variability. As genomic screening technologies become more widely available, pharmacists are ideally suited to use such tools to optimize medication therapy management. The objective of this study was to evaluate the feasibility of implementing personalized medication services into community pharmacy practice and to assess the number of drug therapy problems identified as a result of pharmacogenomic screening.Setting: The study was conducted in 2 busy urban community pharmacies, operating under the brand Shoppers Drug Mart, in Toronto, Ontario.Practice Innovation: Pharmacists offered pharmacogenomic screening as part of their professional services program. Eligible patients received a buccal swab followed by DNA analysis with the use of Pillcheck. Pillcheck is a genotyping assay that translates genomic data and generates a personalized evidence-based report that provides insight into patients' inherited drug metabolic profile. After receiving the report, pharmacists invited patients back to the clinic for interpretation of the results. Clinically significant drug therapy problems were identified and recommendations for medication optimization forwarded to the primary care physician.Results: One hundred patients were enrolled in the study. Average age was 56.7 years, and patients were taking a mean of 4.9 chronic medications. Pharmacists cited the most common reasons for testing as ineffective therapy (43.0%), to address an adverse reaction (32.6%), and to guide initiation of therapy (10.4%). An average of 1.3 drug therapy problems directly related to pharmacogenomic testing were identified per patient. Pharmacist recommendations included change in therapy (60.3%), dose adjustment (13.2%), discontinuation of a drug (4.4%), and increased monitoring (22.1%).Conclusion: These results highlight the readiness of community pharmacists to adopt pharmacogenomic screening into practice and their ability to leverage this novel technology to positively affect medication therapy management. Community pharmacists are ideally suited to both offer personalized medication services and interpret genomic results. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
30. Preanalytical Conditions and DNA Isolation Methods Affect Telomere Length Quantification in Whole Blood.
- Author
-
Tolios, Alexander, Teupser, Daniel, and Holdt, Lesca M.
- Subjects
- *
NUCLEIC acid isolation methods , *TELOMERES , *POLYMERASE chain reaction , *CHROMOSOMES , *COST effectiveness , *BLOOD testing - Abstract
Telomeres are located at chromosome ends and their length (TL) has been associated with aging and human diseases such as cancer. Whole blood DNA is frequently used for TL measurements but the influence of preanalytical conditions and DNA isolation methods on TL quantification has not been thoroughly investigated. To evaluate potential preanalytical as well as methodological bias on TL, anonymized leftover EDTA-whole blood samples were pooled according to leukocyte counts and were incubated with and without actinomycin D to induce apoptosis as a prototype of sample degradation. DNA was isolated from fresh blood pools and after freezing at -80°C. Commercially available kits using beads (Invitrogen), spin columns (Qiagen, Macherey-Nagel and 5prime) or precipitation (Stratec/Invisorb) and a published isopropanol precipitation protocol (IPP) were used for DNA isolation. TL was assessed by qPCR, and normalized to the single copy reference gene 36B4 using two established single-plex and a new multiplex protocol. We show that the method of DNA isolation significantly affected TL (e.g. 1.86-fold longer TL when comparing IPP vs. Invitrogen). Sample degradation led to an average TL decrease of 22% when using all except for one DNA isolation method (5prime). Preanalytical storage conditions did not affect TL with exception of samples that were isolated with the 5prime kit, where a 27% increase in TL was observed after freezing. Finally, performance of the multiplex qPCR protocol was comparable to the single-plex assays, but showed superior time- and cost-effectiveness and required > 80% less DNA. Findings of the current study highlight the need for standardization of whole blood processing and DNA isolation in clinical study settings to avoid preanalytical bias of TL quantification and show that multiplex assays may improve TL/SCG measurements. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
31. Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE).
- Author
-
Droppa, Michal, Tschernow, Dimitri, Müller, Karin A. L., Tavlaki, Elli, Karathanos, Athanasios, Stimpfle, Fabian, Schaeffeler, Elke, Schwab, Matthias, Tolios, Alexander, Siller-Matula, Jolanta M., Gawaz, Meinrad, and Geisler, Tobias
- Subjects
CORONARY heart disease treatment ,ASPIRIN ,CLOPIDOGREL ,ANGIOGRAPHY ,BLOOD platelet aggregation ,HEALTH outcome assessment - Abstract
Objectives: This study was designed to identify the multivariate effect of clinical risk factors on high on-treatment platelet reactivity (HPR) and 12 months major adverse events (MACE) under treatment with aspirin and clopidogrel in patients undergoing non-urgent percutaneous coronary intervention (PCI). Methods: 739 consecutive patients with stable coronary artery disease (CAD) undergoing PCI were recruited. On-treatment platelet aggregation was tested by light transmittance aggregometry. Clinical risk factors and MACE during one-year follow-up were recorded. An independent population of 591 patients served as validation cohort. Results: Degree of on-treatment platelet aggregation was influenced by different clinical risk factors. In multivariate regression analysis older age, diabetes mellitus, elevated BMI, renal function and left ventricular ejection fraction were independent predictors of HPR. After weighing these variables according to their estimates in multivariate regression model, we developed a score to predict HPR in stable CAD patients undergoing elective PCI (PREDICT-STABLE Score, ranging 0-9). Patients with a high score were significantly more likely to develop MACE within one year of follow-up, 3.4% (score 0-3), 6.3% (score 4-6) and 10.3% (score 7-9); odds ratio 3.23, P=0.02 for score 7-9 vs. 0-3. This association was confirmed in the validation cohort. Conclusions: Variability of on-treatment platelet function and associated outcome is mainly influenced by clinical risk variables. Identification of high risk patients (e.g. with high PREDICT-STABLE score) might help to identify risk groups that benefit from more intensified antiplatelet regimen. Additional clinical risk factor assessment rather than isolated platelet function-guided approaches should be investigated in future to evaluate personalized antiplatelet therapy in stable CAD-patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
32. Comparison of Whole Blood RNA Preservation Tubes and Novel Generation RNA Extraction Kits for Analysis of mRNA and MiRNA Profiles.
- Author
-
Häntzsch, Madlen, Tolios, Alexander, Beutner, Frank, Nagel, Dorothea, Thiery, Joachim, Teupser, Daniel, and Holdt, Lesca M.
- Subjects
- *
BLOOD microbiology , *MICRORNA , *EXTRACTION (Chemistry) , *NUCLEIC acid isolation methods , *MESSENGER RNA , *MYOCARDIAL infarction - Abstract
Background: Whole blood expression profiling is frequently performed using PAXgene (Qiagen) or Tempus (Life Technologies) tubes. Here, we compare 6 novel generation RNA isolation protocols with respect to RNA quantity, quality and recovery of mRNA and miRNA. Methods: 3 PAXgene and 3 Tempus Tubes were collected from participants of the LIFE study with (n = 12) and without (n = 35) acute myocardial infarction (AMI). RNA was extracted with 4 manual protocols from Qiagen (PAXgene Blood miRNA Kit), Life Technologies (MagMAX for Stabilized Blood Tubes RNA Isolation Kit), and Norgen Biotek (Norgen Preserved Blood RNA Purification Kit I and Kit II), and 2 (semi-)automated protocols on the QIAsymphony (Qiagen) and MagMAX Express-96 Magnetic Particle Processor (Life Technologies). RNA quantity and quality was determined. For biological validation, RNA from 12 representative probands, extracted with all 6 kits (n = 72), was reverse transcribed and mRNAs (matrix metalloproteinase 9, arginase 1) and miRNAs (miR133a, miR1), shown to be altered by AMI, were analyzed. Results: RNA yields were highest using the Norgen Kit I with Tempus Tubes and lowest using the Norgen Kit II with PAXgene. The disease status was the second major determinant of RNA yields (LIFE-AMI 11.2 vs. LIFE 6.7 µg, p<0.001) followed by the choice of blood collection tube. (Semi-)automation reduced overall RNA extraction time but did not generally reduce hands-on-time. RNA yields and quality were comparable between manual and automated extraction protocols. mRNA expression was not affected by collection tubes and RNA extraction kits but by RT/qPCR reagents with exception of the Norgen Kit II, which led to mRNA depletion. For miRNAs, expression differences related to collection tubes (miR30b), RNA isolation (Norgen Kit II), and RT/qRT reagents (miR133a) were observed. Conclusion: We demonstrate that novel generation RNA isolation kits significantly differed with respect to RNA recovery and affected miRNA but not mRNA expression profiles. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
33. Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model.
- Author
-
Seyfried, Nick, Yurttas, Can, Burkard, Markus, Oswald, Benedikt, Tolios, Alexander, Herster, Franziska, Kauer, Joseph, Jäger, Tarkan, Königsrainer, Ingmar, Thiel, Karolin, Quante, Markus, Rammensee, Hans-Georg, Venturelli, Sascha, Schwab, Matthias, Königsrainer, Alfred, Beckert, Stefan, and Löffler, Markus W.
- Subjects
ADJUVANT chemotherapy ,FLOW cytometry ,MICROMETASTASIS ,THERMOTHERAPY ,PERITONEAL cancer ,COLORECTAL cancer ,OXALIPLATIN - Abstract
Simple Summary: Absence of survival benefits when adding hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin to cytoreductive surgery in peritoneal metastasis from colorectal cancer has recently been shown in the randomized controlled PRODIGE 7 trial. We therefore aimed to investigate the effects of this treatment modality in a preclinical micrometastasis model. Cancer cells were incubated with either patient samples obtained during HIPEC procedures or with defined oxaliplatin-containing solutions prepared according to clinically established HIPEC protocols. Our results demonstrate a limited effectiveness of short-term HIPEC in simulations with oxaliplatin to eliminate micrometastases, although we used platinum-sensitive cell lines for our model. Since these results are in line with findings from current research, our studies might offer further convincing evidence and potential explanations for HIPEC futility observed in clinical application. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) was considered a promising treatment for patients with peritoneal metastasis from colorectal cancer. However, the recently published randomized controlled PRODIGE 7 trial failed to demonstrate survival benefits through the addition of short-term oxaliplatin-based HIPEC. Constituting a complex multifactorial treatment, we investigated HIPEC in a preclinical model concerning the elimination of minimal tumor residues, thereby aiming to better understand the size of effects and respective clinical trial results. Patient samples of peritoneal perfusates obtained during HIPEC treatments and oxaliplatin-containing solutions at clinically relevant dosages, conforming with established HIPEC protocols, were assessed regarding their ability to eliminate modelled ~100 µm thickness cancer cell layers. Impedance-based real-time cell analysis and classical end-point assays were used. Flow cytometry was employed to determine the effect of different HIPEC drug solvents on tumor cell properties. Effectiveness of peritoneal perfusate patient samples and defined oxaliplatin-containing solutions proved limited but reproducible. HIPEC simulations for 30 min reduced the normalized cell index below 50% with peritoneal perfusates from merely 3 out of 9 patients within 72 h, indicating full-thickness cytotoxic effects. Instead, prolonging HIPEC to 1 h enhanced these effects and comprised 7 patients' samples, while continuous drug exposure invariably resulted in complete cell death. Further, frequently used drug diluents caused approximately 25% cell size reduction within 30 min. Prolonging oxaliplatin exposure improved effectiveness of HIPEC to eliminate micrometastases in our preclinical model. Accordingly, insufficient penetration depth, short exposure time, and the physicochemical impact of drug solvents may constitute critical factors. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Increased platelet Ca2+ channel Orai1 expression upon platelet activation and in patients with acute myocardial infarction.
- Author
-
Tolios, Alexander, Gatidis, Sergios, Münzer, Patrick, Guoxing Liu, Towhid, Syeda T., Karathanos, Athanasios, Tavlaki, Elli, Geisler, Tobias, Seizer, Peter, May, Andreas E., Bigalke, Boris, Borst, Oliver, Gawaz, Meinrad, and Lang, Florian
- Published
- 2013
- Full Text
- View/download PDF
35. Thrombin-sensitive expression of the store operated Ca2+ channel Orai1 in platelets.
- Author
-
Münzer, Patrick, Tolios, Alexander, Pelzl, Lisann, Schmid, Evi, Schmidt, Eva-Maria, Walker, Britta, Fröhlich, Henning, Borst, Oliver, Gawaz, Meinrad, and Lang, Florian
- Subjects
- *
THROMBIN , *CALCIUM channels , *GENETIC regulation , *BLOOD platelets , *MESSENGER RNA , *PHOSPHATIDYLINOSITOL 3-kinases , *KINASE inhibitors - Abstract
Highlights: [•] In blood platelets, thrombin upregulates protein abundance of Ca2+ channel Orai1. [•] The effect is paralleled by transient formation of mRNA from pre-RNA. [•] The effect is blunted by inhibition of translation but not by inhibition of transcription. [•] The effect is blunted by pharmacological inhibition of phosphoinositide-3-kinase. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
36. Stimulation of platelet apoptosis by balhimycin.
- Author
-
Towhid, Syeda T., Tolios, Alexander, Münzer, Patrick, Schmidt, Eva-Maria, Borst, Oliver, Gawaz, Meinrad, Stegmann, Evi, and Lang, Florian
- Subjects
- *
BLOOD platelets , *APOPTOSIS , *VANCOMYCIN , *GLYCOPEPTIDES , *METHICILLIN-resistant staphylococcus aureus , *ANTIBIOTICS , *DRUG side effects - Abstract
Abstract: Glycopeptides, such as vancomycin, are powerful antibiotics against methicillin-resistant Staphylococcus aureus. Balhimycin, a glycopeptide antibiotic isolated from Amycolatopsis balhimycina, is similarly effective as vancomycin. Side effects of vancomycin include triggering of platelet apoptosis, which is characterized by cell shrinkage and by cell membrane scrambling with phosphatidylserine exposure at the cell surface. Stimulation of apoptosis may involve increase of cytosolic Ca2+ activity, ceramide formation, mitochondrial depolarization and/or caspase activation. An effect of balhimycin on apoptosis has, however, never been reported. The present study thus tested whether balhimycin triggers platelet apoptosis. Human blood platelets were treated with balhimycin and cell volume was estimated from forward scatter, phosphatidylserine exposure from annexin V-binding, cytosolic Ca2+ activity from fluo-3AM fluorescence, ceramide formation utilizing antibodies, mitochondrial potential from DiOC6 fluorescence, and caspase-3 activity utilizing antibodies. As a result, a 30min exposure to balhimycin significantly decreased cell volume (⩾1μg/ml), triggered annexin V binding (⩾1μg/ml), increased cytosolic Ca2+ activity (⩾1μg/ml), stimulated ceramide formation (⩾10μg/ml), depolarized mitochondria (⩾1μg/ml) and activated caspase-3 (⩾1μg/ml). Cell membrane scrambling and caspase-3 activation were virtually abrogated by removal of extracellular Ca2+. Cell membrane scrambling was not significantly blunted by pancaspase inhibition with zVAD-FMK (1μM). In conclusion, balhimycin triggers cell membrane scrambling of platelets, an effect dependent on Ca2+, but not on activation of caspases. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
37. Stimulation of Platelet Death by Vancomycin.
- Author
-
Towhid, Syeda T., Schmidt, Eva-Maria, Tolios, alexander, Münzer, Patrick, Schmid, Evi, Borst, Oliver, Gawaz, Meinrad, Stegmann, Evi, and Lang, Florian
- Subjects
BLOOD platelets ,VANCOMYCIN ,DRUG side effects ,APOPTOSIS ,THROMBOCYTOPENIA treatment ,IMMUNE system ,PHOSPHATIDYLSERINES ,CALCIUM ions ,BACTERIAL antibodies - Abstract
Background/Aims: Side effects of vancomycin, a widely used antibiotic, include thrombocytopenia. The vancomycin-induced thrombocytopenia has been attributed to immune reactions. At least in theory, thrombocytopenia could result in part from the triggering of apoptosis, which results in cell shrinkage and cell membrane scrambling with subsequent phosphatidylserine exposure at the cell surface. The cell membrane scrambling could be initiated by a signaling involving increase of cytosolic Ca
2+ activity, ceramide formation, mitochondrial depolarization and/or caspase activation. Vancomycin has indeed been shown to trigger neutrophil apoptosis. An effect of vancomycin on platelet apoptosis has, however, never been tested. The present study thus explored the effect of vancomycin on platelet activation and apoptosis. Methods: Human blood platelets were exposed to vancomycin and forward scatter was utilized to estimate cell volume, annexin V-binding to quantify phosphatidylserine (PS) exposure, Fluo-3 AM fluorescence to estimate cytosolic Ca2+ activity ([Ca2+ ]i ), antibodies to quantify ceramide formation and immunofluorescence to quantify protein abundance of active caspase-3. Results: A 30 minutes exposure to vancomycin (≥1 μg/ ml) decreased cell volume, triggered annexin V-binding, increased [Ca2+ ]i , activated caspase 3, stimulated ceramide formation, triggered release of thromboxane B2 , and upregulated surface expression of CD62P (P-selectin) as well as activated integrin αllb β3 . Annexin V-binding and upregulation of CD62P (P-selectin) and integrin αllb β3 was significantly blunted by removal of extracellular Ca2+ . Annexin V-binding was not significantly blunted by pan-caspase inhibitor zVAD-FMK (1 μM). In conclusion, vancomycin results in platelet activation and suicidal platelet death with increase of [Ca2+ ]i , caspase-3 activation, cell membrane scrambling and cell shrinkage. Activation and cell membrane scrambling required the presence of Ca2+ , but not activation of caspases. Conclusion: Vancomycin exposure leads to platelet activation and apoptosis. Copyright © 2013 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
38. Translational regulation of the serum- and glucocorticoid-inducible kinase-1 (SGK1) in platelets
- Author
-
Pelzl, Lisann, Tolios, Alexander, Schmidt, Eva-Maria, Alesutan, Ioana, Walker, Britta, Münzer, Patrick, Borst, Oliver, Gawaz, Meinrad, and Lang, Florian
- Subjects
- *
GLUCOCORTICOIDS , *PROTEIN kinases , *BLOOD platelets , *SERUM , *THROMBIN , *CALCIUM channels , *MEGAKARYOCYTES - Abstract
Abstract: Activation of platelets by thrombin opens pore forming channel protein Orai1 with subsequent store operated Ca2+ entry (SOCE) and Ca2+ dependent platelet granule release, integrin αIIbβ3 activation, adhesion, aggregation and thrombus formation. Orai1 and thus SOCE as well as platelet activation are up-regulated by the serum- and glucocorticoid-inducible kinase-1 (SGK1), which transcriptionally regulates Orai1 expression in megakaryocytes and thus determines Orai1 protein abundance in mature, circulating platelets. As platelets are devoid of nuclei, they are unable to modify protein abundance by regulation of transcription. However, they contain mRNA and thus could express novel protein by stimulation of protein translation. Translation is sensitive to actin polymerization and phosphoinositide-3-kinase (PI3K). Translational regulation of SGK1 expression has never been described before. The present study thus explored whether thrombin regulates SGK1 expression in platelets. As a result, according to RT-PCR mRNA encoding SGK1 is present in circulating platelets and significantly decreased by activation of platelets with thrombin (1U/ml). The protein abundance of SGK1 is significantly enhanced by thrombin treatment, an effect significantly decreased by inhibition of translation with puromycin (100nM) but not by inhibition of transcription with actinomycin (4μg/ml). The increase of SGK1 protein abundance is blunted by inhibition of PI3K with wortmannin (100nM) or LY294002 (25μM), and by disruption of the cytoskeleton with cytochalasin B (1μM). In conclusion, activation of platelets with thrombin stimulates the translation of SGK1. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
39. HbA1c testing in the community pharmacy: A new strategy to improve care for patients with diabetes.
- Author
-
Papastergiou, John, Rajan, Amy, Diamantouros, Artemis, Zervas, John, Chow, Justin, and Tolios, Peter
- Published
- 2012
- Full Text
- View/download PDF
40. A comprehensive survey of artificial intelligence adoption in European laboratory medicine: current utilization and prospects.
- Author
-
Cadamuro, Janne, Carobene, Anna, Cabitza, Federico, Debeljak, Zeljko, De Bruyne, Sander, van Doorn, William, Johannes, Elias, Frans, Glynis, Özdemir, Habib, Martin Perez, Salomon, Rajdl, Daniel, Tolios, Alexander, and Padoan, Andrea
- Abstract
As the healthcare sector evolves, Artificial Intelligence’s (AI’s) potential to enhance laboratory medicine is increasingly recognized. However, the adoption rates and attitudes towards AI across European laboratories have not been comprehensively analyzed. This study aims to fill this gap by surveying European laboratory professionals to assess their current use of AI, the digital infrastructure available, and their attitudes towards future implementations.We conducted a methodical survey during October 2023, distributed via EFLM mailing lists. The survey explored six key areas: general characteristics, digital equipment, access to health data, data management, AI advancements, and personal perspectives. We analyzed responses to quantify AI integration and identify barriers to its adoption.From 426 initial responses, 195 were considered after excluding incomplete and non-European entries. The findings revealed limited AI engagement, with significant gaps in necessary digital infrastructure and training. Only 25.6 % of laboratories reported ongoing AI projects. Major barriers included inadequate digital tools, restricted access to comprehensive data, and a lack of AI-related skills among personnel. Notably, a substantial interest in AI training was expressed, indicating a demand for educational initiatives.Despite the recognized potential of AI to revolutionize laboratory medicine by enhancing diagnostic accuracy and efficiency, European laboratories face substantial challenges. This survey highlights a critical need for strategic investments in educational programs and infrastructure improvements to support AI integration in laboratory medicine across Europe. Future efforts should focus on enhancing data accessibility, upgrading technological tools, and expanding AI training and literacy among professionals. In response, our working group plans to develop and make available online training materials to meet this growing educational demand. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Data flow in clinical laboratories: could metadata and peridata bridge the gap to new AI-based applications?
- Author
-
Padoan, Andrea, Cadamuro, Janne, Frans, Glynis, Cabitza, Federico, Tolios, Alexander, De Bruyne, Sander, van Doorn, William, Elias, Johannes, Debeljak, Zeljko, Perez, Salomon Martin, Özdemir, Habib, and Carobene, Anna
- Subjects
- *
INFORMATION technology , *ARTIFICIAL intelligence , *DATA management , *INFORMATION storage & retrieval systems , *PATHOLOGICAL laboratories - Abstract
In the last decades, clinical laboratories have significantly advanced their technological capabilities, through the use of interconnected systems and advanced software. Laboratory Information Systems (LIS), introduced in the 1970s, have transformed into sophisticated information technology (IT) components that integrate with various digital tools, enhancing data retrieval and exchange. However, the current capabilities of LIS are not sufficient to rapidly save the extensive data, generated during the total testing process (TTP), beyond just test results. This opinion paper discusses qualitative types of TTP data, proposing how to divide laboratory-generated information into two categories, namely metadata and peridata. Being both metadata and peridata information derived from the testing process, it is proposed that the first is useful to describe the characteristics of data, while the second is for interpretation of test results. Together with standardizing preanalytical coding, the subdivision of laboratory-generated information into metadata or peridata might enhance ML studies, also by facilitating the adherence of laboratory-derived data to the Findability, Accessibility, Interoperability, and Reusability (FAIR) principles. Finally, integrating metadata and peridata into LIS can improve data usability, support clinical utility, and advance AI model development in healthcare, emphasizing the need for standardized data management practices. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Systematic Analysis of the Transcriptome Profiles and Co-Expression Networks of Tumour Endothelial Cells Identifies Several Tumour-Associated Modules and Potential Therapeutic Targets in Hepatocellular Carcinoma.
- Author
-
Mohr, Thomas, Katz, Sonja, Paulitschke, Verena, Aizarani, Nadim, Tolios, Alexander, and Scartozzi, Mario
- Subjects
ENDOTHELIAL cells ,DNA ,COMPLEMENT (Immunology) ,SEQUENCE analysis ,CANCER invasiveness ,INFLAMMATION ,CELL physiology ,APOPTOSIS ,IMMUNE system ,NUCLEOTIDES ,CELLULAR signal transduction ,ENDOGLIN ,GENE expression ,GENE expression profiling ,PATHOLOGIC neovascularization ,CELL proliferation ,CELL lines ,HEPATOCELLULAR carcinoma - Abstract
Simple Summary: Endothelial cells, the innermost layer of blood vessels, play an essential role in the progression of cancer, particularly liver cancer. To develop cancer therapies targeting those cells, the investigation of gene co-expression networks is of great importance. In this study, we investigated the gene expression profile of tumour endothelial cells. We compared it to endothelial cells from non-tumour liver-tissue. Using gene-network based methods, we could identify genes that may play a unique role in liver cancer progression or be a target for cancer therapy. Additionally, we provided a framework for similar analyses in other cancers. Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related death, with tumour associated liver endothelial cells being thought to be major drivers in HCC progression. This study aims to compare the gene expression profiles of tumour endothelial cells from the liver with endothelial cells from non-tumour liver tissue, to identify perturbed biologic functions, co-expression modules, and potentially drugable hub genes that could give rise to novel therapeutic targets and strategies. Gene Set Variation Analysis (GSVA) showed that cell growth-related pathways were upregulated, whereas apoptosis induction, immune and inflammatory-related pathways were downregulated in tumour endothelial cells. Weighted Gene Co-expression Network Analysis (WGCNA) identified several modules strongly associated to tumour endothelial cells or angiogenic activated endothelial cells with high endoglin (ENG) expression. In tumour cells, upregulated modules were associated with cell growth, cell proliferation, and DNA-replication, whereas downregulated modules were involved in immune functions, particularly complement activation. In ENG
+ cells, upregulated modules were associated with cell adhesion and endothelial functions. One downregulated module was associated with immune system-related functions. Querying the STRING database revealed known functional-interaction networks underlying the modules. Several possible hub genes were identified, of which some (for example FEN1, BIRC5, NEK2, CDKN3, and TTK) are potentially druggable as determined by querying the Drug Gene Interaction database. In summary, our study provides a detailed picture of the transcriptomic differences between tumour and non-tumour endothelium in the liver on a co-expression network level, indicates several potential therapeutic targets and presents an analysis workflow that can be easily adapted to other projects. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
43. Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer.
- Author
-
Yurttas, Can, Hoffmann, Giulia, Tolios, Alexander, Haen, Sebastian P., Schwab, Matthias, Königsrainer, Ingmar, Königsrainer, Alfred, Beckert, Stefan, and Löffler, Markus W.
- Subjects
CETUXIMAB ,HYPERTHERMIC intraperitoneal chemotherapy ,CYTOREDUCTIVE surgery ,COMBINED modality therapy ,ABDOMINAL surgery ,MITOMYCINS ,DRUG carriers - Abstract
Background: Cytoreductive surgery (CRS), followed by hyperthermic intraperitoneal chemotherapy (HIPEC), combines radical surgery with abdominal heated chemotherapy, constituting a multimodal treatment approach. Since clear standards for HIPEC conduct in colorectal carcinoma (CRC) are lacking, we aimed to provide a comprehensive structured survey. Data sources and study eligibility criteria: A systematic literature search was performed in PubMed, with keywords "HIPEC" and "colorectal cancer", according to established guidelines. Articles were systematically screened, selecting 87 publications complemented by 48 publications identified through extended search for subsequent synthesis and evaluation, extracting inter alia details on used drugs, dosage, temperature, exposure times, and carrier solutions. Results: Compiled publications contained 171 reports on HIPEC conduct foremost with mitomycin C and oxaliplatin, but also other drugs and drug combinations, comprising at least 60 different procedures. We hence provide an overview of interconnections between HIPEC protocols, used drugs and carrier solutions as well as their volumes. In addition, HIPEC temperatures and dosing benchmarks, as well as an estimate of in vivo resulting drug concentrations are demonstrated. Conclusions and implications: Owing to recent developments, HIPEC conduct and practices need to be reassessed. Unfortunately, imprecise and lacking reporting is frequent, which is why minimal information requirements should be established for HIPEC and the introduction of final drug concentrations for comparability reasons seems sensible. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
44. A study of the effects of extracorporeal circulation on the immunologic system of humans
- Author
-
Siminelakis, S., Bossinakou, I., Antoniou, F., Pallanza, Z., Tolios, J., Vasilogiannakopoulou, D., Kasapli, M., Parigori, P., and Chlapoutakis, E.
- Published
- 1996
- Full Text
- View/download PDF
45. INTERCEPT Pathogen Reduction in Platelet Concentrates, in Contrast to Gamma Irradiation, Induces the Formation of trans-Arachidonic Acids and Affects Eicosanoid Release during Storage
- Author
-
Gerda C. Leitner, Gerhard Hagn, Laura Niederstaetter, Andrea Bileck, Kerstin Plessl-Walder, Michaela Horvath, Vera Kolovratova, Andreas Tanzmann, Alexander Tolios, Werner Rabitsch, Philipp Wohlfarth, and Christopher Gerner
- Subjects
eicosanoids ,high-resolution mass spectrometry ,liquid chromatography ,pathogen reduction ,platelet concentrates ,platelets ,Microbiology ,QR1-502 - Abstract
Pathogen inactivation techniques for blood products have been implemented to optimize clinically safe blood components supply. The INTERCEPT system uses amotosalen together with ultraviolet light wavelength A (UVA) irradiation. Irradiation-induced inactivation of nucleic acids may actually be accompanied by modifications of chemically reactive polyunsaturated fatty acids known to be important mediators of platelet functions. Thus, here, we investigated eicosanoids and the related fatty acids released upon treatment and during storage of platelet concentrates for 7 days, complemented by the analysis of functional and metabolic consequences of these treatments. Metabolic and functional issues like glucose consumption, lactate formation, platelet aggregation, and clot firmness hardly differed between the two treatment groups. In contrast to gamma irradiation, here, we demonstrated that INTERCEPT treatment immediately caused new formation of trans-arachidonic acid isoforms, while 11-hydroxyeicosatetraenoic acid (11-HETE) and 15-HETE were increased and two hydroperoxyoctadecadienoic acid (HpODE) isoforms decreased. During further storage, these alterations remained stable, while the release of 12-lipoxygenase (12-LOX) products such as 12-HETE and 12-hydroxyeicosapentaenoic acid (12-HEPE) was further attenuated. In vitro synthesis of trans-arachidonic acid isoforms suggested that thiol radicals formed by UVA treatment may be responsible for the INTERCEPT-specific effects observed in platelet concentrates. It is reasonable to assume that UVA-induced molecules may have specific biological effects which need to be further investigated.
- Published
- 2022
- Full Text
- View/download PDF
46. Effects of intravenous nifedipine on pulmonary and cardiac performance during CABG
- Author
-
Antoniou, F., Tolios, J., Siminelakis, S., Kourtessis, A., Alexopoulos, P., Papaioannou, J., and Fannie, Antoniou
- Published
- 1994
- Full Text
- View/download PDF
47. Early repolarization pattern in middle-aged adults with chest pain resembling atypical angina: Is this pattern associated with significant coronary artery disease?
- Author
-
George Michas, MD, MRes, PhD, Gerasimos Gavrielatos, MD, MSc, Konstantinos Grigoriou, MD, George Papagiannis, MD, Panagiotis Tolios, MD, George Mplazakis, MD, Athanasios Paschalis, MD, and Athanasios Trikas, MD, PhD
- Subjects
Early repolarization ,Coronary artery disease ,Angina ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2017
- Full Text
- View/download PDF
48. Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).
- Author
-
Michal Droppa, Dimitri Tschernow, Karin A L Müller, Elli Tavlaki, Athanasios Karathanos, Fabian Stimpfle, Elke Schaeffeler, Matthias Schwab, Alexander Tolios, Jolanta M Siller-Matula, Meinrad Gawaz, and Tobias Geisler
- Subjects
Medicine ,Science - Abstract
ObjectivesThis study was designed to identify the multivariate effect of clinical risk factors on high on-treatment platelet reactivity (HPR) and 12 months major adverse events (MACE) under treatment with aspirin and clopidogrel in patients undergoing non-urgent percutaneous coronary intervention (PCI).Methods739 consecutive patients with stable coronary artery disease (CAD) undergoing PCI were recruited. On-treatment platelet aggregation was tested by light transmittance aggregometry. Clinical risk factors and MACE during one-year follow-up were recorded. An independent population of 591 patients served as validation cohort.ResultsDegree of on-treatment platelet aggregation was influenced by different clinical risk factors. In multivariate regression analysis older age, diabetes mellitus, elevated BMI, renal function and left ventricular ejection fraction were independent predictors of HPR. After weighing these variables according to their estimates in multivariate regression model, we developed a score to predict HPR in stable CAD patients undergoing elective PCI (PREDICT-STABLE Score, ranging 0-9). Patients with a high score were significantly more likely to develop MACE within one year of follow-up, 3.4% (score 0-3), 6.3% (score 4-6) and 10.3% (score 7-9); odds ratio 3.23, P=0.02 for score 7-9 vs. 0-3. This association was confirmed in the validation cohort.ConclusionsVariability of on-treatment platelet function and associated outcome is mainly influenced by clinical risk variables. Identification of high risk patients (e.g. with high PREDICT-STABLE score) might help to identify risk groups that benefit from more intensified antiplatelet regimen. Additional clinical risk factor assessment rather than isolated platelet function-guided approaches should be investigated in future to evaluate personalized antiplatelet therapy in stable CAD-patients.
- Published
- 2015
- Full Text
- View/download PDF
49. Preanalytical Conditions and DNA Isolation Methods Affect Telomere Length Quantification in Whole Blood.
- Author
-
Alexander Tolios, Daniel Teupser, and Lesca M Holdt
- Subjects
Medicine ,Science - Abstract
Telomeres are located at chromosome ends and their length (TL) has been associated with aging and human diseases such as cancer. Whole blood DNA is frequently used for TL measurements but the influence of preanalytical conditions and DNA isolation methods on TL quantification has not been thoroughly investigated. To evaluate potential preanalytical as well as methodological bias on TL, anonymized leftover EDTA-whole blood samples were pooled according to leukocyte counts and were incubated with and without actinomycin D to induce apoptosis as a prototype of sample degradation. DNA was isolated from fresh blood pools and after freezing at -80°C. Commercially available kits using beads (Invitrogen), spin columns (Qiagen, Macherey-Nagel and 5prime) or precipitation (Stratec/Invisorb) and a published isopropanol precipitation protocol (IPP) were used for DNA isolation. TL was assessed by qPCR, and normalized to the single copy reference gene 36B4 using two established single-plex and a new multiplex protocol. We show that the method of DNA isolation significantly affected TL (e.g. 1.86-fold longer TL when comparing IPP vs. Invitrogen). Sample degradation led to an average TL decrease of 22% when using all except for one DNA isolation method (5prime). Preanalytical storage conditions did not affect TL with exception of samples that were isolated with the 5prime kit, where a 27% increase in TL was observed after freezing. Finally, performance of the multiplex qPCR protocol was comparable to the single-plex assays, but showed superior time- and cost-effectiveness and required > 80% less DNA. Findings of the current study highlight the need for standardization of whole blood processing and DNA isolation in clinical study settings to avoid preanalytical bias of TL quantification and show that multiplex assays may improve TL/SCG measurements.
- Published
- 2015
- Full Text
- View/download PDF
50. Comparison of whole blood RNA preservation tubes and novel generation RNA extraction kits for analysis of mRNA and MiRNA profiles.
- Author
-
Madlen Häntzsch, Alexander Tolios, Frank Beutner, Dorothea Nagel, Joachim Thiery, Daniel Teupser, and Lesca M Holdt
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Whole blood expression profiling is frequently performed using PAXgene (Qiagen) or Tempus (Life Technologies) tubes. Here, we compare 6 novel generation RNA isolation protocols with respect to RNA quantity, quality and recovery of mRNA and miRNA. METHODS: 3 PAXgene and 3 Tempus Tubes were collected from participants of the LIFE study with (n = 12) and without (n = 35) acute myocardial infarction (AMI). RNA was extracted with 4 manual protocols from Qiagen (PAXgene Blood miRNA Kit), Life Technologies (MagMAX for Stabilized Blood Tubes RNA Isolation Kit), and Norgen Biotek (Norgen Preserved Blood RNA Purification Kit I and Kit II), and 2 (semi-)automated protocols on the QIAsymphony (Qiagen) and MagMAX Express-96 Magnetic Particle Processor (Life Technologies). RNA quantity and quality was determined. For biological validation, RNA from 12 representative probands, extracted with all 6 kits (n = 72), was reverse transcribed and mRNAs (matrix metalloproteinase 9, arginase 1) and miRNAs (miR133a, miR1), shown to be altered by AMI, were analyzed. RESULTS: RNA yields were highest using the Norgen Kit I with Tempus Tubes and lowest using the Norgen Kit II with PAXgene. The disease status was the second major determinant of RNA yields (LIFE-AMI 11.2 vs. LIFE 6.7 µg, p
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.